NCT02179736已完成不适用
A Post Market Evaluation After Treatment of Nasolabial Folds
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Galderma R&D
- 入组人数
- 114
- 试验地点
- 1
- 主要终点
- Effectiveness of study treatment in correction of nasolabial folds up to 12 months after a single treatment:
研究概览
简要总结
This is an open, non-comparative study to evaluate effectiveness and safety of Restylane in correction of nasolabial folds up to 12 months after the initial treatment, and to evaluate the safety of repeat treatment of the nasolabial folds 12 months after the initial treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Markedly indurate defects such as significant mid-face volume loss or prominent commissures.
- •Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or in the area to be treated.
- •Subjects with known hypersensitivity to any ingredient of the study product or anaesthesia used in the study.
- •Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation, (e.g. non-steriodal anti-inflammatory drugs, acetylsalicylic acid, Omega 3 and Vitamin E) within 2 weeks prior to treatment, or a history of bleeding disorders.
- •Concomitant treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids. (Inhaled corticoids are allowed).
- •Cancerous or pre-cancerous lesions in the treatment area.
- •Subjects who have performed aesthetic facial surgery.
- •Tissue augmenting therapy with non-permanent filler or neurotoxin below the lower orbital rim in the last 12 months.
- •Facial laser treatment or chemical peeling below the lower orbital rim during the last 6 months.
- •Permanent implant or filler, including fat-injections, placed in the area to be treated.
- •Women who are pregnant or breast feeding or who are planning to become pregnant during the study period.
- •Participation in any other clinical study within 30 days prior to inclusion.
- •Any medical condition that in the opinion of the investigator would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may affect the general condition or may require frequent medical treatment, psychiatric disorders or subjects not likely to comply to study procedures or to avoid other facial cosmetic treatments below the lower orbital rim).
- •Subjects who are study site staff for this study, or close relatives (defined as parents, siblings, children or spouse) of the study site staff, as well as subjects who are employed by the sponsor company, or close relatives of employees at the sponsor company.
结局指标
主要结局
Effectiveness of study treatment in correction of nasolabial folds up to 12 months after a single treatment:
时间窗: up to 12 months
* Investigator evaluated wrinkle severity using wrinkle severity rating scale (WSRS) * Improvement in subject and investigator rated global aesthetic improvement (GAIS) compared to baseline. * Subject satisfaction
次要结局
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(Up to 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Restylane® for the Treatment of Tear Trough DeformityTear Trough Eyelid DeformityNCT04486794Erevna Innovations Inc.42
已完成
不适用
Restylane Perlane to Shape the Nasal Dorsum and/or Nasal RootNasal AugmentationNCT02216851Galderma R&D132
已完成
不适用
Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial FoldsNasolabial Folds in Chinese PopulationNCT02432742Galderma R&D100
已完成
4 期
Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne ScarsHealthy VolunteersNCT03127384Galderma R&D49
已完成
4 期
An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital LidocaineAcne ScarsNCT01807455Galderma R&D12